Literature DB >> 12745022

Cellular retention of radioactivity and increased radiation dose. Model experiments with EGF-dextran.

Asa Liljegren Sundberg1, Erik Blomquist, Jörgen Carlsson, Ann-Charlott Steffen, Lars Gedda.   

Abstract

Targeting of tumor cells with radiolabeled biomolecules is a possible approach to inactivate disseminated tumor cells. However, rapid degradation of the biomolecules after cellular internalization and subsequent excretion of the radioactivity is a problem. We studied the possibility of using dextran as a carrier of radionuclides to improve the intracellular retention. An EGF-dextran conjugate, aimed for targeting of tumor cells overexpressing the EGF-receptor, was used as model. Retention tests were performed with (125)I on different parts: [(125)I]-EGF-dextran-[(125)I], [(125)I]-EGF-dextran and EGF-dextran-[(125)I]. Comparisons were made with [(125)I]-EGF. The radiolabeled compounds were incubated with cultured glioma cells for different times. The cellular retention of radioactivity was then measured for up to 24 h. Expected radiation doses at the cellular level were calculated assuming that (131)I, instead of (125)I, was coupled to EGF and EGF-dextran. The results indicated that the EGF-part of the conjugate was degraded and the EGF-attached radioactivity was rapidly excreted, whereas radioactivity on dextran was retained intracellularly to a high degree, i.e. 70-80% of the radioactivity bound to dextran was still cell-associated after 24 h. The retention after 24 h was significantly higher (p < 0.001) when the radioactivity was on the dextran instead of the EGF-part. The radiolabeled EGF-dextran had a notably high specific radioactivity; up to 11 MBq/microg. There was potential for at least hundred times increased radiation dose per receptor interaction when the radioactivity was on the dextran part. The advantage with radioactivity on the dextran part was the high cellular retention and the high specific radioactivity (higher than previously reported for other residualizing labels) without severe loss of receptor specific binding. Thus, dextran seems suitable as a carrier of radionuclides aimed for therapy and gives potential for a highly increased radiation dose.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12745022     DOI: 10.1016/s0969-8051(02)00421-3

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  3 in total

Review 1.  Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression.

Authors:  J Carlsson; Z P Ren; K Wester; A L Sundberg; N E Heldin; G Hesselager; M Persson; L Gedda; V Tolmachev; H Lundqvist; E Blomquist; M Nistér
Journal:  J Neurooncol       Date:  2006-03       Impact factor: 4.130

2.  Affibody-mediated tumour targeting of HER-2 expressing xenografts in mice.

Authors:  Ann-Charlott Steffen; Anna Orlova; Maria Wikman; Fredrik Y Nilsson; Stefan Ståhl; Gregory P Adams; Vladimir Tolmachev; Jörgen Carlsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-15       Impact factor: 9.236

3.  Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy.

Authors:  Jörgen Carlsson; Veronika Eriksson; Bo Stenerlöw; Hans Lundqvist
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-05-23       Impact factor: 9.236

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.